Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 1

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 1
---
-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☒

If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards † provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.

17,016,694 Common Shares

<div align='center'>Clearmind Medicine Inc.</div>

This prospectus relates to
the resale, by the selling shareholders identified in this prospectus, of up to 17,016,694 common shares, no par value per share, or the
common shares, of Clearmind Medicine Inc., consisting of (i) 16,970,241 common shares issued or issuable upon the conversion of the Initial
Promissory Notes (as defined below) in the principal amount of $2.5 million, including common shares that may become issuable pursuant
to certain anti-dilution adjustments described more fully in the Promissory Notes and (ii) 46,453 common shares that were issued to certain
selling shareholders as equity